The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial
Open accessAbstract
Importance: Older patients and those with comorbidities who are infected with SARS-CoV-2 may be at increased risk of hospitalization and death. Sotrovimab is a neutralizing antibody for the treatment of high-risk patients to prevent COVID-19 progression. Objective: To evaluate the efficacy and adverse events of sotrovimab in preventing progression of mild to moderate COVID-19 to severe disease. Design, Setting, and Participants: Randomized clinical trial including 1057 nonhospitalized patients with symptomatic, mild to moderate COVID-19 and at least 1 risk factor for progression conducted at 57 sites in Brazil, Canada, Peru, Spain, and the US from August 27, 2020, through March 11, 2021; follow-up data were collected through April 8, 2021. Interventions: Patients were randomized (1:1) to an intravenous infusion with 500 mg of sotrovimab (n = 528) or placebo (n = 529). Main Outcomes and Measures: The primary outcome was the proportion of patients with COVID-19 progression through day 29 (all-cause hospitalization lasting >24 hours for acute illness management or death); 5 secondary outcomes were tested in hierarchal order, including a composite of all-cause emergency department (ED) visit, hospitalization of any duration for acute illness management, or death through day 29 and progression to severe or critical respiratory COVID-19 requiring supplemental oxygen or mechanical ventilation. Results: Enrollment was stopped early for efficacy at the prespecified interim analysis. Among 1057 patients randomized (median age, 53 years [IQR, 42-62], 20% were ≥65 years of age, and 65% Latinx), the median duration of follow-up was 103 days for sotrovimab and 102 days for placebo. All-cause hospitalization lasting longer than 24 hours or death was significantly reduced with sotrovimab (6/528 [1%]) vs placebo (30/529 [6%]) (adjusted relative risk [RR], 0.21 [95% CI, 0.09 to 0.50]; absolute difference, -4.53% [95% CI, -6.70% to -2.37%]; P < .001). Four of the 5 secondary outcomes were statistically significant in favor of sotrovimab, including reduced ED visit, hospitalization, or death (13/528 [2%] for sotrovimab vs 39/529 [7%] for placebo; adjusted RR, 0.34 [95% CI, 0.19 to 0.63]; absolute difference, -4.91% [95% CI, -7.50% to -2.32%]; P < .001) and progression to severe or critical respiratory COVID-19 (7/528 [1%] for sotrovimab vs 28/529 [5%] for placebo; adjusted RR, 0.26 [95% CI, 0.12 to 0.59]; absolute difference, -3.97% [95% CI, -6.11% to -1.82%]; P = .002). Adverse events were infrequent and similar between treatment groups (22% for sotrovimab vs 23% for placebo); the most common events were diarrhea with sotrovimab (n = 8; 2%) and COVID-19 pneumonia with placebo (n = 22; 4%). Conclusions and Relevance: Among nonhospitalized patients with mild to moderate COVID-19 and at risk of disease progression, a single intravenous dose of sotrovimab, compared with placebo, significantly reduced the risk of a composite end point of all-cause hospitalization or death through day 29. The findings support sotrovimab as a treatment option for nonhospitalized, high-risk patients with mild to moderate COVID-19, although efficacy against SARS-CoV-2 variants that have emerged since the study was completed is unknown. Trial Registration: ClinicalTrials.gov Identifier: NCT04545060.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Wiersinga, W. J., Rhodes, A., Cheng, A. C., Peacock, S. J., & Prescott, H. C. (2020) · JAMA · doi:10.1001/jama.2020.12839 · Cited by 4,609
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2349-y · Cited by 1,885
Structural and functional analysis of a potent sarbecovirus neutralizing antibody
Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · doi:10.1101/2020.04.07.023903 · Cited by 1,752
Coronavirus disease 2019 case surveillance—United States, January 22–May 30, 2020.
Stokes, E. K., Zambrano, L. D., Anderson, K. N., Marder, E. P., Raz, K. M., El Burai Felix, S., Tie, Y., & Fullerton, K. E. (2020) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6924e2 · Cited by 1,538
Zheng, S., Fan, J., Yu, F., Feng, B., Lou, B., Zou, Q., Xie, G., Lin, S., Wang, R., Yang, X., et al. (2020) · BMJ · doi:10.1136/bmj.m1443 · Cited by 1,440
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
Chen, P., Nirula, A., Heller, B., Gottlieb, R. L., Boscia, J., Morris, J., Huhn, G., Cardona, J., Mocherla, B., Stosor, V., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2029849 · Cited by 1,282
Higgins (2002) · doi:10.1002/(issn)1097-0258 · Cited by 1,248
Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab
Gupta, A., Gonzalez-Rojas, Y., Juarez, E., Crespo Casal, M., Moya, J., Falci, D. R., Sarkis, E., Solis, J., Zheng, H., Scott, N., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107934 · Cited by 1,086
Self-citationSARS-CoV-2 viral load is associated with increased disease severity and mortality
Fajnzylber, J., Regan, J., Coxen, K., Corry, H., Wong, C., Rosenthal, A., Worrall, D., Giguel, F., Piechocka-Trocha, A., Atyeo, C., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19057-5 · Cited by 906
VanBlargan, L. A., Errico, J. M., Halfmann, P. J., Zost, S. J., Crowe, J. E., Purcell, L. A., Kawaoka, Y., Corti, D., Fremont, D. H., & Diamond, M. S. (2022) · Nature Medicine · doi:10.1038/s41591-021-01678-y · Cited by 705
A perspective on potential antibody-dependent enhancement of SARS-CoV-2
Arvin, A. M., Fink, K., Schmid, M. A., Cathcart, A., Spreafico, R., Havenar-Daughton, C., Lanzavecchia, A., Corti, D., & Virgin, H. W. (2020) · Nature · doi:10.1038/s41586-020-2538-8 · Cited by 485
Self-citationStarr, T. N., Greaney, A. J., Dingens, A. S., & Bloom, J. D. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100255 · Cited by 470
Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies
Lempp, F. A., Soriaga, L. B., Montiel-Ruiz, M., Benigni, F., Noack, J., Park, Y.-J., Bianchi, S., Walls, A. C., Bowen, J. E., Zhou, J., et al. (2021) · Nature · doi:10.1038/s41586-021-03925-1 · Cited by 297
Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
Cameroni, E., Bowen, J. E., Rosen, L. E., Saliba, C., Zepeda, S. K., Culap, K., Pinto, D., VanBlargan, L. A., Marco, A. D., di Iulio, J., et al. (2021) · Nature · doi:10.1038/d41586-021-03825-4 · Cited by 254
Flores, L. E., Frontera, W. R., Andrasik, M. P., del Rio, C., Mondríguez-González, A., Price, S. A., Krantz, E. M., Pergam, S. A., & Silver, J. K. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.37640 · Cited by 243
Gaudinski, M. R., Coates, E. E., Houser, K. V., Chen, G. L., Yamshchikov, G., Saunders, J. G., Holman, L. A., Gordon, I., Plummer, S., Hendel, C. S., et al. (2018) · PLOS Medicine · doi:10.1371/journal.pmed.1002493 · Cited by 241
Focosi, D., & Maggi, F. (2021) · Reviews in Medical Virology · doi:10.1002/rmv.2231 · Cited by 160
Lustig, Y., Zuckerman, N. S., Nemet, I., Atari, N., Kliker, L., Regev‐Yochay, G., Sapir, E., Mor, O., Alroy‐Preis, S., Mendelson, E., et al. (2021) · Eurosurveillance · doi:10.2807/1560-7917.es.2021.26.26.2100557 · Cited by 151
Late Complications of COVID-19; a Systematic Review of Current Evidence.
SeyedAlinaghi, S., Afsahi, A. M., MohsseniPour, M., Behnezhad, F., Salehi, M. A., Barzegary, A., Mirzapour, P., Mehraeen, E., & Dadras, O. (2021) · Archives of Academic Emergency Medicine · doi:10.22037/aaem.v9i1.1058 · Cited by 134
Experiences of Latinx Individuals Hospitalized for COVID-19: A Qualitative Study
Cervantes, L., Martín, M., Frank, M. G., Farfan, J. F., Kearns, M. T., Rubio, L. A., Tong, A., González, A. M., Camacho, C. G., Collings, A., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.0684 · Cited by 117
Excess mortality among Latino people in California during the COVID-19 pandemic
Riley, A. R., Chen, Y., Matthay, E. C., Glymour, M. M., Torres, J. M., Fernández, A., & Bibbins-Domingo, K. B. (2021) · SSM - Population Health · doi:10.1016/j.ssmph.2021.100860 · Cited by 108
501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab in vitro
Liu, H., Wei, P., Zhang, Q., Chen, Z., Aviszus, K., Downing, W., Peterson, S. W., Reynoso, L., Downey, G. P., Frankel, S. K., et al. (2021) · mAbs · doi:10.1080/19420862.2021.1919285 · Cited by 97
Han, A., Poon, J. L., Powers, J. H., Leidy, N. K., Yu, R., & Memoli, M. J. (2018) · BMC Infectious Diseases · doi:10.1186/s12879-018-3220-8 · Cited by 39
Inadequate Minority Representation within SARS-CoV-2 Vaccine Trials
Craft, J. F., Travassos, M. A., Palacios, C. F., & Openshaw, J. J. (2020) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.20-1294 · Cited by 11
Metadata
- Authors
- Gupta, A., Gonzalez-Rojas, Y., Juarez, E., Crespo Casal, M., Moya, J., Rodrigues Falci, D., Sarkis, E., Solis, J., Zheng, H., Scott, N., Cathcart, A. L., Parra, S., Sager, J. E., Austin, D., Peppercorn, A., Alexander, E., Yeh, W. W., Brinson, C., Aldinger, M., Shapiro, A. E., COMET-ICE Investigators, Free, A., Johnson, K., Cordasco, E., Little, R., Bajwa, A., Doshi, A., Focil, A., Hussain, R. (., Bostick, G., Somodevilla, G., Ali, H., Kowalczyk, J., Mittal, S., Caso, J., Goisse, M., Espinal, L., Zepeda, L., Nguyen, T., Martinez, L., Alvarez, G., Pucillo, R., Seep, M., Parikh, N., Escobar, V., Curra, A., Dal Maso, V., O'Mahony, J., Ramacciotti, E., Diaz, J., Luz, K., Ruane, P., Mochlera, B., Roldan Sanchez, J., Hernandez, L., Fernandez, A., Leavitt, G., Azizad, M., Afzal, H., Fatakia, A., Narejos Perez, S., Stadnik, C. M., Gorgos, L., Sachdeva, Y., Segura, P., Quandros, C., Perry, R., & Sher, L.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2022-04-05
- Volume
- 327
- Issue
- 13
- Pages
- 1236
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W4220848096
- Cited by
- 279
- References
- 26
- FWCI
- 30.73
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.